Consider adding larotrectinib as an option for select patients based on the FDA approval for the treatment of adult and pediatric patients with solid tumors that:
- have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.

Based on the data in the noted reference and discussion, the panel consensus was to include larotrectinib as an option, if NTRK gene fusion positive, for second-line therapy for locally advanced/metastatic pancreatic cancer, and therapy for recurrent disease. This is a category 2A recommendation.

Reference: